Publications dans lesquelles il/elle collabore avec Miguel Mínguez Pérez (14)

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

2022

  1. Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU

    Journal of Clinical Medicine, Vol. 11, Núm. 13

  2. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953

2020

  1. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents

    Journal of Gastroenterology and Hepatology (Australia), Vol. 35, Núm. 12, pp. 2080-2087

  2. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

  3. Switching to a second thiopurine in adult and elderly patients with inflammatory bowel disease: A nationwide study from the eneida registry

    Journal of Crohn's and Colitis, Vol. 14, Núm. 9, pp. 1290-1298

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

  3. Increased risk of thiopurine-related adverse events in elderly patients with IBD

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788

  4. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial

    Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535

2018

  1. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 8, pp. 839-851

2017

  1. Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial

    Journal of Crohn's and Colitis, Vol. 11, Núm. 11, pp. 1293-1301

  2. Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study

    Inflammatory Bowel Diseases, Vol. 23, Núm. 10, pp. 1840-1846

2016

  1. Physician Perspectives on Unresolved Issues in the Management of Ulcerative Colitis: The UC Horizons Project

    Inflammatory Bowel Diseases, Vol. 22, Núm. 3, pp. 583-589